Vilin Bio Med Ltd.

•

vilinbiomed.co.inBSE: -NSE: VILINBIO

Market Cap₹ 83 Cr.

Current Price

High / Low₹ 54 / 19

Stock P/E42.9

Book Value₹ 19

Price to Book1.97

Dividend Yield0.00 %

ROCE10.7 %

ROE7.5 %

Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company is almost debt free
Company has delivered good sales growth of 29.3% CAGR over last 5 years
Working capital cycle has improved - days down from 376 to 181
Stock looks reasonably valued - P/E of 42.9 is below its historical median
Company comfortably covers its interest (42.3x coverage)

CONS

Company has a low return on equity of 3.1% over last 3 years
Promoter holding has decreased over last 2 years: -7.9pp
Company has a low return on capital employed of 6.5%
Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -2.81x)
Equity base is being diluted - shares outstanding up 53.3%
Operating margins have contracted to 7.6% from 21.1%

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	SUNPHARMA	1899.00	37.67	455633.71	0.84	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9100.00	82.59	241576.41	0.33	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4850.00	84.58	184478.41	0.78	566.00	3.28	4921.00	57.32	19.27	33.81
4.	CIPLA	1385.00	33.19	111888.39	0.94	785.55	-39.18	7119.28	4.13	16.00	16.73
5.	ZYDUSLIFE	1121.00	24.78	111820.18	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
6.	LAURUSLABS	1840.00	90.93	99417.45	0.11	362.07	123.94	2026.31	29.10	18.20	31.50
7.	LUPIN	2111.00	17.46	96528.82	0.85	1416.98	16.01	8276.89	34.28	28.86	29.59
8.	DRREDDY	1154.00	29.89	96322.06	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
9.	MANKIND	2328.55	47.09	96179.61	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
10.	AUROPHARMA	1653.30	25.62	95127.23	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
11.	GLENMARK	2427.00	38.10	68495.93	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	VILINBIO	54.25	42.89	82.73	0.00	—	—	—	—	10.73	—

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

No quarterly results found

We don't have this information yet. Please check back later.

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	17	12	11	12	16	15	42
	16	11	10	10	15	14	39
Operating Profit	1	1	1	3	1	1	3
OPM %	5.35%	7.12%	6.83%	20.90%	5.17%	5.31%	7.56%
	0	0	0	0	0	0	0
Interest	0	0	1	1	1	1	0
Depreciation	0	0	0	0	0	0	0
Profit before Tax	0	0	0	2	0	0	3
Tax %	16.31%	24.71%	24.83%	30.12%	27.89%	26.90%	32.10%
Net Profit	0	0	0	1	0	0	2
EPS	0.49	0.37	0.10	1.25	0.12	0.16	1.26
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

COMPOUNDED SALES GROWTH

10 Years:: —
5 Years:: 29%
3 Years:: 51%

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: 74%
3 Years:: 16%

STOCK PRICE CAGR

10 Years:: —
5 Years:: —
3 Years:: 33%
1 Year:: 120%

RETURN ON EQUITY

10 Years:: —
5 Years:: 5%
3 Years:: 3%
Last Year:: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	3	3	3	10	14	14	15
	4	4	4	1	9	9	13
	5	6	5	5	7	3	0
Trade Payables	2	1	1	1	2	1	3
	0	0	0	1	1	1	3
Total Liabilities	14	14	14	18	32	28	35
	2	2	2	2	1	1	3
Capital Work in Progress	0	0	0	0	0	2	0
	2	2	2	1	4	4	7
	0	0	8	0	6	9	16
Cash & Bank	0	0	0	0	6	0	1
	10	10	2	15	15	12	7
Total Assets	14	14	14	18	32	28	35

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-1	-1	0	-1	-7	1	1
Cash from Investing	-0	0	0	-0	0	-1	-0
Cash from Financing	2	1	-0	2	9	-5	1
	0	-0	-0	-0	2	-6	1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
PER SHARE
EPS (₹)	0.49	0.37	0.10	1.25	0.12	0.16	1.26
Book Value (₹)	21.94	22.31	22.41	10.73	16.37	16.53	18.60
Dividend per Share (₹)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash EPS (₹)	0.57	0.46	0.31	1.42	0.21	0.24	1.45
PROFITABILITY
Operating Margin %	5.41%	7.34%	6.83%	21.10%	5.17%	5.31%	7.56%
Net Margin %	0.96%	1.04%	0.30%	10.11%	1.03%	1.51%	4.56%
ROE %	2.24%	1.66%	0.46%	13.78%	0.97%	0.97%	7.50%
ROCE %	5.09%	4.89%	4.31%	17.17%	4.47%	4.16%	10.73%
	1.16%	0.87%	0.24%	7.97%	0.65%	0.74%	6.15%
EFFICIENCY
Debtor Days	158	232	251	198	130	175	106
Inventory Days	46	65	71	47	62	109	50
Payable Days	49	54	30	47	44	46	23
	154	243	292	199	148	239	133
FINANCIAL HEALTH
Debt to Equity (x)	0.63x	0.75x	0.72x	0.46x	0.30x	0.11x	0.01x
Interest Coverage (x)	1.48x	1.36x	1.09x	3.75x	1.29x	1.36x	42.29x
	1.76x	2.19x	2.22x	1.24x	2.01x	4.30x	4.25x
GROWTH
Revenue Growth %	0.00%	-30.32%	-4.27%	9.79%	28.36%	-6.30%	185.37%
Operating Profit Growth %	0.00%	-5.51%	-10.50%	237.38%	-56.07%	10.02%	154.45%
Net Profit Growth %	0.00%	-25.22%	-72.30%	3605.36%	-86.96%	37.68%	762.66%
	0.00%	0.00%	-72.31%	0.00%	-90.70%	37.71%	689.08%
VALUATION
P/E (x)	0.00x	0.00x	0.00x	0.00x	163.23x	127.26x	28.97x
P/B (x)	0.00x	0.00x	0.00x	0.00x	1.16x	1.23x	1.97x
Dividend Yield %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0.00x	0.00x	11.12x	0.00x	23.91x	24.67x	17.10x

Shareholding Pattern

Numbers in percentages

	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	64.52	64.52	64.09	63.89	63.89	63.89	63.65	59.57	56.65
FIIs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
DIIs	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	35.48	35.48	35.91	36.11	36.11	36.11	36.35	40.43	43.35

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

No announcements filed.

News

Recent coverage and analyst commentary for VILINBIO

Loading news…

🤖

AI Stock Analyst

Vilin Bio Med Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

SUNPHARMA

1899.00

37.67

455633.71

0.84

2901.23

26.53

15299.88

10.98

19.11

28.81

DIVISLAB

9100.00

82.59

241576.41

0.33

902.00

65.50

3080.00

27.80

21.51

40.75

TORNTPHARM

4850.00

84.58

184478.41

0.78

566.00

3.28

4921.00

57.32

19.27

33.81

CIPLA

1385.00

33.19

111888.39

0.94

785.55

-39.18

7119.28

4.13

16.00

16.73

ZYDUSLIFE

1121.00

24.78

111820.18

0.09

990.20

-34.90

8017.00

23.97

21.39

24.54

LAURUSLABS

1840.00

90.93

99417.45

0.11

362.07

123.94

2026.31

29.10

18.20

31.50

LUPIN

2111.00

17.46

96528.82

0.85

1416.98

16.01

8276.89

34.28

28.86

29.59

DRREDDY

1154.00

29.89

96322.06

0.69

435.60

-69.10

8099.80

-5.21

13.75

10.63

MANKIND

2328.55

47.09

96179.61

0.04

574.09

29.12

4030.59

12.89

13.24

26.30

AUROPHARMA

1653.30

25.62

95127.23

0.24

1032.03

25.22

9150.35

17.44

12.76

20.54

GLENMARK

2427.00

38.10

68495.93

0.10

482.83

927.88

4018.48

31.35

20.35

20.03

VILINBIO

54.25

42.89

82.73

0.00

—

10.73

—

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Operating Profit

OPM %

5.35%

7.12%

6.83%

20.90%

5.17%

5.31%

7.56%

Interest

Depreciation

Profit before Tax

Tax %

16.31%

24.71%

24.83%

30.12%

27.89%

26.90%

32.10%

Net Profit

EPS

0.49

0.37

0.10

1.25

0.12

0.16

1.26

Dividend Payout %

0.00%

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Equity Capital

Trade Payables

Total Liabilities

Capital Work in Progress

Cash & Bank

Total Assets

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

-1

-7

Cash from Investing

-0

-1

-0

Cash from Financing

-0

-5

-0

-6

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

PER SHARE

EPS (₹)

0.49

0.37

0.10

1.25

0.12

0.16

1.26

Book Value (₹)

21.94

22.31

22.41

10.73

16.37

16.53

18.60

Dividend per Share (₹)

0.00

Cash EPS (₹)

0.57

0.46

0.31

1.42

0.21

0.24

1.45

PROFITABILITY

Operating Margin %

5.41%

7.34%

6.83%

21.10%

5.17%

5.31%

7.56%

Net Margin %

0.96%

1.04%

0.30%

10.11%

1.03%

1.51%

4.56%

ROE %

2.24%

1.66%

0.46%

13.78%

0.97%

7.50%

ROCE %

5.09%

4.89%

4.31%

17.17%

4.47%

4.16%

10.73%

1.16%

0.87%

0.24%

7.97%

0.65%

0.74%

6.15%

EFFICIENCY

Debtor Days

158

232

251

198

130

175

106

Inventory Days

109

Payable Days

154

243

292

199

148

239

133

FINANCIAL HEALTH

Debt to Equity (x)

0.63x

0.75x

0.72x

0.46x

0.30x

0.11x

0.01x

Interest Coverage (x)

1.48x

1.36x

1.09x

3.75x

1.29x

1.36x

42.29x

1.76x

2.19x

2.22x

1.24x

2.01x

4.30x

4.25x

GROWTH

Revenue Growth %

0.00%

-30.32%

-4.27%

9.79%

28.36%

-6.30%

185.37%

Operating Profit Growth %

0.00%

-5.51%

-10.50%

237.38%

-56.07%

10.02%

154.45%

Net Profit Growth %

0.00%

-25.22%

-72.30%

3605.36%

-86.96%

37.68%

762.66%

0.00%

-72.31%

0.00%

-90.70%

37.71%

689.08%

VALUATION

P/E (x)

0.00x

163.23x

127.26x

28.97x

P/B (x)

0.00x

1.16x

1.23x

1.97x

Dividend Yield %

0.00%

0.00x

11.12x

0.00x

23.91x

24.67x

17.10x

Sep 2023

Mar 2024

Sep 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

64.52

64.09

63.89

63.65

59.57

56.65

FIIs

0.00

DIIs

0.00

Government

0.00

35.48

35.91

36.11

36.35

40.43

43.35

Vilin Bio Med Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Vilin Bio Med Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI